Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
215
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 273 publications
(216 citation statements)
references
References 22 publications
1
215
0
Order By: Relevance
“…Based on the former studies, it has been demonstrated that Anlotinib may have great potential of inhibiting VEGFR, PDGFR, and FGFR, which possess a high correlation with cancer genesis and progression. Therefore, we rationally evaluated the relationship between VEGFA, PDGFRA, and FGFR4 expression level and the BC patients' relapse free survival (RFS) time in public database K‐M Plotter .…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Based on the former studies, it has been demonstrated that Anlotinib may have great potential of inhibiting VEGFR, PDGFR, and FGFR, which possess a high correlation with cancer genesis and progression. Therefore, we rationally evaluated the relationship between VEGFA, PDGFRA, and FGFR4 expression level and the BC patients' relapse free survival (RFS) time in public database K‐M Plotter .…”
Section: Resultsmentioning
confidence: 99%
“…Recently, the application of a number of targeted molecular therapies, including antiangiogenic agents therapy, has attracted increasing interest because of the toxicities and the emergence of resistance to the conventional chemotherapy . Anlotinib is a novel member of the tyrosine kinase inhibitors (TKIs) family, which has shown a potential inhibitory efficacy on numerous receptor tyrosine kinases implicated in cancer progression, such as VEGFR‐2 and ‐3 (vascular endothelial growth factor receptor types 2 and 3), FGF (fibroblast growth factor), and PDGF‐α/β (platelet‐derived growth factor‐α/β) . The outcomes of preclinical trials demonstrated that Anlotinib exhibited efficacy in a host of solid tumors, including non‐small‐cell lung cancer (NSCLC), hepatocarcinoma, gastric cancer, renal carcinoma, and soft tissue sarcoma .…”
Section: Introductionmentioning
confidence: 99%
“…Different from typical antiangiogenesis drugs such as rh‐endostatin and bevacizumab, anlotinib inhibits both neoplastic angiogenesis and tumor growth pathways . Actually, it has been reported that activation of the EGFR pathway increases the production of tumor‐secreted VEGF that acts on endothelial cells to promote angiogenesis .…”
Section: Discussionmentioning
confidence: 99%
“…Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1‐3, fibroblast growth factor receptor (FGFR) 1‐4, platelet‐derived growth factor receptors (PDGFR) α/β, c‐Kit, and Met, that is, has a broad spectrum of inhibitory action on angiogenesis and malignancies growth. In addition, anlotinib showed antitumor activity on tumor cells carrying mutations in epidermal growth factor receptor (EGFR) . Phase I clinical trial has established the safety profile of anlotinib and identified commended dose of 12 mg once daily at the 2 weeks on treatment followed by 1 week off treatment schedule .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation